The stock of Intra-Cellular Therapies Inc (NASDAQ: ITCI) has increased by 24.74 when compared to last closing price of 64.76. Despite this, the company has experienced a 17.72% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-02-27 that NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024 at 11:10 a.m. ET in Boston, MA.
Is It Worth Investing in Intra-Cellular Therapies Inc (NASDAQ: ITCI) Right Now?
ITCI has 36-month beta value of 1.04. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ITCI is 94.22M, and currently, short sellers hold a 3.68% ratio of that float. The average trading volume of ITCI on April 16, 2024 was 746.63K shares.
ITCI’s Market Performance
The stock of Intra-Cellular Therapies Inc (ITCI) has seen a 17.72% increase in the past week, with a 24.70% rise in the past month, and a 19.73% gain in the past quarter. The volatility ratio for the week is 3.22%, and the volatility levels for the past 30 days are at 3.06% for ITCI. The simple moving average for the past 20 days is 19.69% for ITCI’s stock, with a 30.79% simple moving average for the past 200 days.
Analysts’ Opinion of ITCI
Many brokerage firms have already submitted their reports for ITCI stocks, with Robert W. Baird repeating the rating for ITCI by listing it as a “Outperform.” The predicted price for ITCI in the upcoming period, according to Robert W. Baird is $83 based on the research report published on January 03, 2024 of the current year 2024.
TD Cowen, on the other hand, stated in their research note that they expect to see ITCI reach a price target of $75. The rating they have provided for ITCI stocks is “Outperform” according to the report published on December 11th, 2023.
Morgan Stanley gave a rating of “Overweight” to ITCI, setting the target price at $80 in the report published on April 20th of the previous year.
ITCI Trading at 17.45% from the 50-Day Moving Average
After a stumble in the market that brought ITCI to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 6.14% of gains for the given period.
Volatility was left at 3.06%, however, over the last 30 days, the volatility rate increased by 3.22%, as shares surge +23.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.73% upper at present.
During the last 5 trading sessions, ITCI rose by +17.34%, which changed the moving average for the period of 200-days by +29.95% in comparison to the 20-day moving average, which settled at $68.25. In addition, Intra-Cellular Therapies Inc saw 12.79% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ITCI starting from Mates Sharon, who sale 20,565 shares at the price of $65.21 back on Mar 11 ’24. After this action, Mates Sharon now owns 1,050,309 shares of Intra-Cellular Therapies Inc, valued at $1,341,123 using the latest closing price.
Hineline Lawrence J., the SVP of Finance, CFO of Intra-Cellular Therapies Inc, sale 10,121 shares at $65.96 during a trade that took place back on Mar 11 ’24, which means that Hineline Lawrence J. is holding 0 shares at $667,587 based on the most recent closing price.
Stock Fundamentals for ITCI
Current profitability levels for the company are sitting at:
- -0.34 for the present operating margin
- 0.93 for the gross margin
The net margin for Intra-Cellular Therapies Inc stands at -0.3. The total capital return value is set at -0.26. Equity return is now at value -22.39, with -18.84 for asset returns.
Based on Intra-Cellular Therapies Inc (ITCI), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -7.33. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 36.65.
Currently, EBITDA for the company is -158.85 million with net debt to EBITDA at 0.82. When we switch over and look at the enterprise to sales, we see a ratio of 17.06. The receivables turnover for the company is 4.05for trailing twelve months and the total asset turnover is 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.41.
Conclusion
To put it simply, Intra-Cellular Therapies Inc (ITCI) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
